Meeting
2020 Genitourinary Cancers Symposium
Disease progression among patients who receive available bladder preservation therapies after failure of BCG therapy in the SEER-Medicare data.
Authors
Ashish M. Kamat
The University of Texas MD Anderson Cancer Center, Houston, TX
Ashish M. Kamat , Mihaela V. Georgieva , Jinlin Song , Iryna Bocharova , Kun Qian , Amy Guo , Min Yang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 453)
Abstract #
453
Poster Bd #
F20
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Population based trends in intravesical gemcitabine use among patients with high-risk non-muscle invasive bladder cancer.
First Author: Stephen B. Williams
Poster
2024 ASCO Genitourinary Cancers Symposium
Guiding adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient-derived organoids.
First Author: Martin Egger
Poster
2023 ASCO Genitourinary Cancers Symposium
Study of real-world treatment patterns and adherence to bacillus Calmette-Guerin (BCG) in the context of guideline recommendations for patients with high-risk non-muscle invasive bladder cancer (NMIBC).
First Author: Franklin D Gaylis
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Metronomic oral cyclophosphamide as maintenance therapy in metastatic pancreatic ductal adenocarcinoma.
First Author: Michele Reni